Cure Pharmaceutical Holding Corp, a vertically integrated drug delivery and product development company, announced today that it has signed a partnership agreement with Biopharmaceutical Research Company, (BRC), an active Drug Enforcement Administration (DEA) license holder, to produce federally-compliant cannabis-based medical products. Currently, CURE uses its Schedule 1 DEA license for the development of Cannabis (THC) oral film products and other psychoactive substances and manufactures multiple commercial Cannabidiol (CBD) products in compliance with the 2018 U.S. Farm Bill. These products are shelf-stable, feature high bioavailability, and offer multiple taste-masking and flavor solutions. With this partnership, BRC, which was recently awarded one of the only federal production licenses from the DEA to produce clean, consistent, and compliant cannabis for federally approved researchers across the United States.

Mmp News Author, Medical Marijuana Program Connection, 06/10/2021 19:34:00

Open article: